UCSF

UC San Francisco Previously Published Works

Title

Peritrigonal and temporo-occipital heterotopia with corpus callosum and cerebellar dysgenesis

Permalink

https://escholarship.org/uc/item/9nq1c8z5

Journal

Neurology, 79(12)

ISSN

0028-3878

Authors

Pisano, Tiziana Barkovich, A James Leventer, Richard J et al.

Publication Date

2012-09-18

DOI

10.1212/wnl.0b013e31826aac88

Peer reviewed

Peritrigonal and temporo-occipital heterotopia with corpus callosum and cerebellar dysgenesis

Tiziana Pisano, MD* A. James Barkovich, MD Richard J. Leventer, MBBS, PhD Waney Squier, MD Ingrid E. Scheffer, MBBS, PhD Elena Parrini, PhD Susan Blaser, MD Carla Marini, MD, PhD Stephen Robertson, MD Gaetano Tortorella, MD Felix Rosenow, MD Pierre Thomas, MD, PhD George McGillivray, MD Eva Andermann, MD Frederick Andermann, MD Samuel F. Berkovic, **MBBS** William B. Dobyns, MD Renzo Guerrini, MD*

Correspondence & reprint requests to Dr. Guerrini: r.guerrini@meyer.it

Editorial, page 1192



ABSTRACT

Objective: To describe a homogeneous subtype of periventricular nodular heterotopia (PNH) as part of a newly defined malformation complex.

Methods: Observational study including review of brain MRI and clinical findings of a cohort of 50 patients with PNH in the temporo-occipital horns and trigones, mutation analysis of the *FLNA* gene, and anatomopathologic study of a fetal brain.

Results: There were 28 females and 22 males. All were sporadic with the exception of an affected mother and son. Epilepsy occurred in 62%, cerebellar signs in 56%, cognitive impairment in 56%, and autism in 12%. Seventy percent were referred within the 3rd year of life. Imaging revealed a normal cerebral cortex in 76% and abnormal cortical folding in 24%. In all patients the hippocampi were under-rotated and in 10% they merged with the heterotopia. Cerebellar dysgenesis was observed in 84% and a hypoplastic corpus callosum in 60%. There was no gender bias or uneven gender distribution of clinical and anatomic severity. No mutations of *FLNA* occurred in 33 individuals examined. Heterotopia in the fetal brain revealed cytoarchitectonic characteristics similar to those associated with *FLNA* mutations; cortical pathology was not typical of polymicrogyria. Cerebellar involvement was more severe and the hippocampi appeared simple and under-rotated.

Conclusions: This series delineates a malformation complex in which PNH in the trigones and occipito-temporal horns is associated with hippocampal, corpus callosum, and cerebellar dysgenesis. This subtype of PNH is distinct from classic PNH caused by *FLNA* mutations. *Neurology*® **2012;79:1244-1251**

GLOSSARY

BPNH = bilateral periventricular nodular heterotopia; **dHPLC** = denaturing high-performance liquid chromatography; **DSM-IV** = Diagnostic and Statistical Manual of Mental Disorders, 4th edition; **PNH** = periventricular nodular heterotopia; **WAIS** = Wechsler Adult Intelligence Scale-Revised.

Periventricular nodular heterotopia (PNH) is a neuronal migration disorder in which a subset of neurons fails to migrate into the developing cerebral cortex and is detectable as single or multiple nodules lining the ventricular surface.^{1,2}

Clinical presentation, brain imaging, and genetic causes of PNH are extremely heterogeneous. At least 15 PNH subclasses have been identified, of which classic bilateral PNH (BPNH) represents the largest subgroup (54%).² Several subtypes are associated with other brain malformations including cerebellar hypoplasia,³ polymicrogyria,⁴ microcephaly,⁵ and hydrocephalus.² Cognitive level is usu-

Go to Neurology.org for full disclosures. Disclosures deemed relevant by the authors, if any, are provided at the end of this article.

Copyright © 2012 by AAN Enterprises, Inc.

^{*}Drs. Pisano and Guerrini contributed equally to this work.

From the Pediatric Neurology and Neurogenetics Unit (T.P., E.P., C.M., R.G.), Children's Hospital A. Meyer-University of Florence, Florence, Italy; Department of Radiology (A.J.B.), University of California, San Francisco; Children's Neuroscience Centre (R.J.L.), Murdoch Childrens Research Institute, University of Melbourne Department of Paediatrics, The Royal Children's Hospital, Melbourne, Australia; Paediatric Neurology Unit (W.S.), John Radcliffe Hospital, Oxford, UK; Epilepsy Research Centre (I.E.S., S.F.B.), Department of Medicine, University of Melbourne, Australia; Diagnostic Inaging (S.B.), The Hospital for Sick Children, University of Melbourne, Royal Children's Hospital, Melbourne, Australia; Diagnostic Imaging (S.B.), The Hospital for Sick Children, University of Toronto, Toronto, Canada; Department of Paediatrics and Child Health (S.R.), Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; Unit of Infantile Neuropsychiatry (G.T.), Department of Medical and Surgical Pediatrics, University Hospital of Messina, Messina, Italy; Department of Neurology (F.R.), Epilepsy Center Hessen, UKGM, Campus Marburg, Philipps-University Marburg, Germany; Unite Fonctionnelle EEG-Epileptologie (P.T.), Service de Neurologie, Hopital Pasteur, Nice, France; Genetic Health Services Victoria (G.M.), Murdoch Children's Research Institute, Royal Children's Research Institute Center for Integrative Brain Research (W.B.D.), Seattle, WA; and Research Institute IRCCS 'Stella Maris' Foundation (R.G.), Pisa, Italy.

ally normal or mildly delayed but can be severely delayed, especially when abnormal cortical development or microcephaly co-occur. About 70% of patients have epilepsy, which is often intractable.⁶

Classic bilateral PNH is an X-linked disorder in which brain MRI demonstrates bilateral, usually symmetric, subependymal nodules, with enlarged cisterna magna or mild cerebellar vermis hypoplasia in some patients. All familial cases with X-linked bilateral PNH and about 26% of sporadic patients harbor mutations of the *filamin A* gene (*FLNA*, OMIM *300049).^{2,7} The large majority of affected individuals are female.^{8,9}

Here we describe 50 patients in whom brain MRI revealed heterotopic nodules that were located along the subependymal temporal and occipital horns and trigones of the lateral ventricles and were associated with under-rotated or malformed hippocampi, malformed corpus callosum, and cerebellar dysgenesis in most. Most patients were brought to medical attention within the first 3 years of life due to developmental delay with cerebellar signs. We performed mutation analysis of FLNA in 33 of the 50 patients and found no mutations of this gene. Neuropathologic study of the brain in a 20-week female fetus exhibiting the same malformation pattern showed cytoarchitectonic characteristics of heterotopic nodules in the periventricular and more superficial white matter and focal disruption of the cerebral cortex. Overall, clinical, imaging, and anatomopathologic findings define a distinct malformation complex and confirm clinical and genetic heterogeneity of PNH.

METHODS Patient recruitment. In a previous clinical, MRI, and genetic study on 182 consecutive patients with PNH,2 we identified 15 phenotypic subclasses, including a distinct subclass that at first sight might have been confused with classic X-linked PNH, but exhibited slight, though distinctive, anatomic differences. In particular, in this subgroup the heterotopic nodules were restricted to the trigones and occipital and temporal horns, surrounding the hippocampi, which were underrotated and rounded. Cerebellar dysgenesis was present in most and corpus callosum abnormalities in some. In order to collect a large number of patients with the same anatomic phenotype and better define the associated clinical spectrum, we started an international collaboration and identified a cohort of 50 individuals. Sixteen of the patients reported here are also part of a series with further analysis of the neuroradiologic features (Mandelstam et al., unpublished data).

We also conducted an anatomo-pathologic study of the brain of a female fetus exhibiting the same malformation pattern.

Standard protocol approvals, registrations, and patient consents. All participating individuals, or the parents in the case of minors, gave informed consent. The study was approved by the human research ethics committee of the Meyer's University Hospital.

Clinical and imaging findings. Clinical information was obtained directly from patients or the referring physicians according to a direct interview or standardized questionnaire.

For each patient we collected information about family history, developmental milestones, age at seizure onset, seizure semiology and severity, neurologic status, and cognitive level. Since patients were evaluated at different centers and had variable ages at the time of study, cognitive level was evaluated using different methods, including the Griffiths Mental Development Scale, the Wechsler Intelligence Scale for Children-Revised, the Wechsler Adult Intelligence Scale-Revised (WAIS), as well as adaptive behavioral criteria.¹⁰ Autism was diagnosed using the DSM-IV. MRI was performed in all individuals using 1.5-3 Tesla systems, with T2-weighted spin echo T2 images and 3-dimensional spoiled gradient echo sequences acquired with 1-1.5 mm partitions and reformatted as 1.5- to 3-mm-thick images in the axial, sagittal, and coronal planes in all patients. We reviewed the MRI scans of the brain of all patients for the following parameters: localization of the nodules, their distribution, shape, and size; hippocampal morphology; appearance of the corpus callosum; ventricular shape and size; cerebral cortical gyral pattern; and cerebellar morphology. We used the term "cerebellar dysgenesis"11 to designate a disturbed folial pattern of the cerebellar cortex, in association with diminished volume of the affected portion of the cerebellum or the whole cerebellum.

We used the term polymicrogyria to designate developmental abnormality of the cerebral cortex characterized on MRI by an abnormal cortical folding, with an excessive number of abnormally small gyri, areas of infolding, variably associated with shallow sulci and thickened cortex. ¹²

Mutation analysis of FLNA. Genomic DNA from 33 out of 50 patients was extracted from peripheral blood leukocytes using a DNA isolation kit (DNAzol, MRC, Cincinnati, OH). The 47 exons of *FLNA* and their respective upstream and downstream intron-exon boundaries were amplified by PCR and analyzed with a WAVE denaturing high-performance liquid chromatography (dHPLC), according to the manufacturer's specifications (Transgenomics, La Jolla, CA). Primer sequences, PCR conditions, and dHPLC analysis sequences are available on request.

Statistical analysis. We applied the Fisher exact test to establish whether significant skewing of the gender ratio existed. We also investigated whether a biased ratio of clinical and anatomic impairment occurred by comparing gender distribution for age at first referral, cognitive impairment, cerebellar dysgenesis, and corpus callosum agenesis or hypoplasia.

RESULTS Clinical and imaging findings. The table summarizes the clinical features. We studied 50 patients (28 female, 22 male), including a mother and her son. Only 1 of the remaining patients, a woman, was known to have had a child, who was a healthy boy. The patients' age at the time of study ranged from 1 to 64 years (mean 17.1 years; median 10.5

Patient	Table	Clinical and radiologic features of 50 patients with PNH and URH							
2 F/7 E/10 mo Foc 10 mo Monthly Mild MR NA Thin CC; cVD 3 M322 E/NA Foc & SG 7y DW N N Thin CC; CVD 4 F/28 Mac 5 mo SG NA Isolated soltune Mild DD Hyp PMC; thin CC; CD 5 M.17 E/11 y Foc & SG 3y DW Mild MR N Thin CC 6 M.284 E/3y Foc & SG 3y DW Mild MR A CD 7 F/28 E/8y SG 8y DW N N No additional findings 9 F/16.4 Nyal5y — — — N N N No additional findings 10 M/29 Mac/2d L.G.S 3y SF Mild MR A PMG; thin CC; CD 11 M/40.3 E/28 y SG 29 y SF N N Thin CC; CVD 12<	Patient	Sex/age, y							Brain MRI abnormalities associated with PNH and URH
3	1	F/7	DD/4 mo	_	_	_	Mod MR	NA	Thin CC; CD
4 F/2.8 Muc 5 mo SG NA Isolated seizure MId DD Hyp PMG: thin CC, CD 5 M/17 E/11 y Foe 8 SG 17 y DW N N Thin CC 6 M/28.4 E/3 y Foe 8 SG 17 y DW MId mod MR Tremor PMG: thin CC, CD and CVD 7 F/28 E/8 y FG 8 y DW Mild MR A CD 8 F/40 E/12 y Foe 8 SG 12 y DW N N N additional findings 9 F/18.4 Nya/5 y — — — N A Nya PMG: thin CC; CD CD CD 10 M/29 Mac/2d LGS 3 y SF Mild MR A PMG: thin CC; CD CD CD CD 11 M/40.3 E/12 y SG 29 y SF N N Thin CC; CD	2	F/7	E/10 mo	Foc	10 mo	Monthly	Mild MR	NA	Thin CC; unilateral CD
5 Mi17 E/11y Foc 8 SG 17y DW N N Thin CC 6 M/26.4 E/3y Foc 8 SG 3y DW Mild-mod MR Tremor PMG; thin CC; CD and CVD 7 F/28 E/8y SG 8y DW M N N No additional findings 8 F/40 E/12y Foc 8 SG 12y DW N N No additional findings 9 F/16.4 Nya/5y — — — N N No additional findings 10 M/29 Mad/2d L LGS 3y SF Mild MR A PMG; thin CC; CD 11 M/40.3 E/129 y Foc 8 SG 12 y DW Mod MR Dys PMG; thin CC; CD 12 M/27 E/129 y Foc 8 SG 12 y DW Mod MR N N additional findings 14 M/12 DD/2y Feb 8 Foc 33 y SF Autism A Dys <th< th=""><th>3</th><th>M/32.2</th><th>E/NA</th><th>Foc & SG</th><th>7 y</th><th>DW</th><th>N</th><th>N</th><th>Thin CC; CVD</th></th<>	3	M/32.2	E/NA	Foc & SG	7 y	DW	N	N	Thin CC; CVD
6 M/26.4 E/3 y Foe & SG 3 y DW Mild-mod MR Tremor PMG; thin CC; CD and CVD 7 F/28 E/BY SG 8 y DW Mild MR A CD 8 F/40 E/12 y Foe & SG 12 y DW N N No additional findings 9 F/16.4 N, will y — — — N A, Nys PMG; thin CC; CD 10 M/29 Mac/2 d LGS 3 y SF Mild MR A PMG; thin CC; CD 11 M/40.3 E/29 y Foc & SG 29 y SF N N Thin CC; CVD 12 M/27 E/12 y SG 12 y DW Mod MR Dys PMG; thin CC; CD 14 M/12 DD/2 y Foc & SG 29 y SF N N N odd/Ind 15 F/64.4 E/19 y Foc & SG 19 y SF N ind MIR N CD 1	4	F/2.8	Mac 5 mo	SG	NA	Isolated seizure	Mild DD	Нур	PMG; thin CC; CD
7 F/28 E/57 SG 8y DW Mild MR A CD 8 F/40 E/12 y Foc 8 SG 12 y DW N N N No additional findings 9 F/16.4 Nys/fsy — — — N N A Nys PMG; thin CC; CD 8 CVD 10 M/29 Mac/2d LGS 3y SF Mild MR A PMG; thin CC; CD 8 CVD 11 M/40.3 E/29 y Foc 8 SG 29 y SF N N Thin CC; CVD 12 M/27 E/12 y SG 12 y DW Mod MR Dys PMG; thin CC; CD 13 F/64 NA — — — Mild MR N No additional findings 14 M/12 DD/2 y Foc 19 y SF A Utism A Nys Thin CC; CVD 16 F/9.6 DD/2 y Foc 8 SG 1y SF Mild MR A Absent CC; CD	5	M/17	E/11 y	Foc & SG	17 y	DW	N	N	Thin CC
8 F/40 E/12 y Foc & SG 12 y DW N N No additional findings 9 F/16.4 Nyul5 y — — — N A, Nyu PMG; unitateral CD 10 M/29 Mac/2d LGS 3 y SF Mild MR A PMG; thin CC; CD & CVD 11 M/40.3 E/29 y Foc & SG 29 y SF N N Thin CC; CD & CVD 12 M/27 E/12 y SG 12 y DW Mod MR Dys PMG; thin CC; CD 13 F/64 NA — — — Mild MR N No additional findings 14 M/12 DD/2 y Feb & Foc 3.3 y SF Autism A. Dys CVD 15 F/9.6 DD/2 y Foc 19 y SF Autism A. Nys Thin CC; CVD 16 F/9.6 DD/2 y Foc & SG 1 y SF Mild MR A Absent CC; CD	6	M/26.4	E/3 y	Foc & SG	3 у	DW	Mild-mod MR	Tremor	PMG; thin CC; CD and CVD
9 F/16.4 Nyu/5 y — — — N A Nys PMG; unitateral CD 10 M/29 Mac/2 d LGS 3 y SF Mild MR A PMG; thin CC; CD & CVD 11 M/40.3 E/29 y Foc & SG 29 y SF N N Thin CC; CVD 12 M/27 E/12 y SG 12 y DW Mod MR Dys Open diditional findings 14 M/12 D/2 y Feb & Foc 3.3 y SF Auttern A Dys CVD 15 F/48.4 E/19 y Foc 19 y SF N A Nys Thin CC; CVD 16 F/96 D/0/2 y — — — Mild MR N CD 17 M/35.5 Mac/5 mo Foc & SG 29 y SF N N Unitateral CD 19 M/3 Mac/3 mo Foc & SG 29 y SF Mild MR A Absent CC; CD 20 <th>7</th> <th>F/28</th> <th>E/8 y</th> <th>SG</th> <th>8 y</th> <th>DW</th> <th>Mild MR</th> <th>Α</th> <th>CD</th>	7	F/28	E/8 y	SG	8 y	DW	Mild MR	Α	CD
10	8	F/40	E/12 y	Foc & SG	12 y	DW	N	N	No additional findings
11 M/40.3 E/29 y Foc & SG 29 y SF N N Thin CC; CVD 12 M/27 E/12 y SG 12 y DW Med MR Dys PMG; thin CC; CD 13 F/64 NA — — Mild MR N No additional findings 14 M/12 DD/2 y Feb & Foc 3.3 y SF Autism A, Dys CVD 15 F/48.4 E/19 y Foc 19 y SF Autism A, Dys Thin CC; CVD 16 F/9.6 DD/2 y — — Mild MR N CD 17 M/35.5 Mac/5 mo Foc & SG 1y SF Mild MR A Absent CC; CD 18 F/37.9 E/29 y Foc & SG 29 y SF N N Unilateral CD 19 M/3 Mac/3 mo Foc & SG 29 y SF N N Unilateral CD 20 M/3.3 Mac/7 mo <th>9</th> <th>F/16.4</th> <th>Nys/5 y</th> <th>_</th> <th>_</th> <th>_</th> <th>N</th> <th>A, Nys</th> <th>PMG; unilateral CD</th>	9	F/16.4	Nys/5 y	_	_	_	N	A, Nys	PMG; unilateral CD
12 M/27 E/12 y SG 12 y DW Mod MR Dys PMG; thin CC; CD 13 F/64 NA	10	M/29	Mac/2 d	LGS	3 у	SF	Mild MR	Α	PMG; thin CC; CD & CVD
13 F/64 NA — — Mild MR N No additional findings 14 M/12 DD/2y Feb & Foc 3.3 y SF Autism A, Dys CVD 15 F/4.18.4 E/19 y Foc 19 y SF N A, Nys Thin CC; CVD 16 F/96 DD/2 y — — — Mild MR N CD 17 M/35.5 Mac/5 mo Foc & SG 1y SF Mild MR A Absent CC; CD 18 F/37.9 E/29 y Foc & SG 29 y SF N N Unilateral CD 19 M/3 Mac/3 mo Foc & SG 29 y SF N N Unilateral CD 19 M/3 Mac/3 mo Foc & SG 11 mo SF Autism Dys Thin CC; CD 20 M/3 Mac/7 mo AD	11	M/40.3	E/29 y	Foc & SG	29 y	SF	N	N	Thin CC; CVD
14 M/12 DD/2 y Feb & Foc 3.3 y SF Autism A, Dys CVD 15 F/48.4 E/19 y Foc 19 y SF N A, Nys Thin CC; CVD 16 F/9.6 DD/2 y — — Mild MR N CD 17 M/35.5 Mac/5 mo Foc & SG 1 y SF Mild MR A Absent CC; CD 18 F/37.9 E/29 y Foc & SG 1 y SF Mild MR A Absent CC; CD 19 M/3 Mac/5 mo Foc & SG 29 y SF N N Unilisteral CD 19 M/3 Mac/7 mo Foc & SG 11 mo SF Autism Dys Thin CC; CD 20 M/3.3 Mac/7 mo Foc 2 y SF Mild DD Hyp No additional findings 21 F/50.3 DD/3 y Foc 7 y Monthly Mild MR Pyp Thin CC; CD 22	12	M/27	E/12 y	SG	12 y	DW	Mod MR	Dys	PMG; thin CC; CD
15 F/48.4 E/19 y Foc 19 y SF N A, Nys Thin CC; CVD 16 F/9.6 DD/2 y — — Mild MR N CD 17 M/35.5 Mac/5 mo Foc & SG 1 y SF Mild MR A Absent CC; CD 18 F/37.9 E/28 y Foc & SG 1 y SF Mild MR A Absent CC; CD 19 M/3 Mac/3 mo Foc & SG 11 mo SF N N Unilateral CD 19 M/3 Mac/3 mo Foc & SG 11 mo SF Autism Dys Thic CC; CD 20 M/3.3 Mac/7 mo Foc 2 y SF Mild DD Hyp No additional findings 21 F/50.3 DD/3 y Foc 2 y SF Mild DD Hyp No additional findings 21 F/7.6 DD/2 y NA NA NA NA NA NA NA NA N	13	F/64	NA	_	_	_	Mild MR	N	No additional findings
16 F/9.6 DD/2 y — — Mild MR N CD 17 M/35.5 Mac/5 mo Foc 8 SG 1 y SF Mild MR A Absent CC; CD 18 F/37.9 E/29 y Foc 8 SG 1 y SF N N Unilateral CD 19 M/3 Mac/3 mo Foc 8 SG 11 mo SF Autism Dys Thin CC; CD 20 M/3.3 Mac/7 mo Foc 2 y SF Mild DD Hyp No additional findings 21 F/50.3 DD/3 y Foc 7 y Monthly Mild MR Dysm CD 22 M/7.2 DD/2 y NA NA NA NA NA PMG; hypoplastic CC 23 M/20 DD/3 mo — — — Mild MR Hyp Thin CC; CVD 24 F/7.6 DD/2 y NA NA NA NA NA NA NA Thin CC; CVD <	14	M/12	DD/2 y	Feb & Foc	3.3 y	SF	Autism	A, Dys	CVD
17 M/35.5 Mac/5 mo Foc & SG 1 y SF Mild MR A Absent CC; CD 18 F/37.9 E/29 y Foc & SG 29 y SF N N Unilateral CD 19 M/3 Mac/3 mo Foc & SG 11 mo SF Autism Dys Thin CC; CD 20 M/3.3 Mac/7 mo Foc & 2 y SF Mild DD Hyp No additional findings 21 F/50.3 DD/3 y Foc & 7 y Monthly Mild MR Dysm CD 22 M/7.2 DD/2 y NA NA NA NA NA PMG; hypoplastic CC 23 M/20 DD/3 mo — — — Mild MR Hyp Thin CC; CVD 24 F/7.6 DD/2 y NA NA<	15	F/48.4	E/19 y	Foc	19 y	SF	N	A, Nys	Thin CC; CVD
18 F/37.9 E/29 y Foc & SG 29 y SF N N Unilateral CD 19 M/3 Mac/3 mo Foc & SG 11 mo SF Autism Dys Thin CC; CD 20 M/3.3 Mac/7mo Foc 2 y SF Mild DD Hyp No additional findings 21 F/50.3 DD/3 y Foc 7 y Monthly Mild MR Dysm CD 22 M/7.2 DD/2 y NA NA NA NA NA PMG; hypoplastic CC 23 M/20 DD/3 mo — — — Mild MR Hyp Thin CC; CVD 24 F/7.6 DD/2 y NA NA NA NA NA Thin CC; CVD 25 M/33.1 DD/3 y Foc <3 y	16	F/9.6	DD/2 y	_	_	_	Mild MR	N	CD
19 M/3 Mac/3 mo Foc & SG 11 mo SF Autism Dys Thin CC; CD 20 M/3.3 Mac/7mo Foc 2 y SF Mild DD Hyp No additional findings 21 F/50.3 DD/3 y Foc 7 y Monthly Mild MR Dysm CD 22 M/7.2 DD/2 y NA NA NA NA NA PMG; hypoplastic CC 23 M/20 DD/3 mo — — — Mild MR Hyp Thin CC; CVD 24 F/7.6 DD/2 y NA NA NA NA N Thin CC; CVD 25 M/33.1 DD/3 y Foc <3 y	17	M/35.5	Mac/5 mo	Foc & SG	1 y	SF	Mild MR	Α	Absent CC; CD
20 M/3.3 Mac/7mo Foc 2 y SF Mild DD Hyp No additional findings 21 F/50.3 DD/3 y Foc 7 y Monthly Mild MR Dysm CD 22 M/7.2 DD/2 y NA NA NA NA PMG; hypoplastic CC 23 M/20 DD/3 mo — — — Mild MR Hyp Thin CC; CVD 24 F/7.6 DD/2 y NA NA NA NA N Thin CC; CVD 25 M/33.1 DD/3 y Foc <3 y	18	F/37.9	E/29 y	Foc & SG	29 y	SF	N	N	Unilateral CD
21 F/50.3 DD/3 y Foc 7 y Monthly Mild MR Dysm CD 22 M/7.2 DD/2 y NA NA NA NA NA PMG; hypoplastic CC 23 M/20 DD/3 mo — — — Mild MR Hyp Thin CC; CVD 24 F/7.6 DD/2 y NA NA NA NA N Thin CC; CVD 25 M/33.1 DD/3 y Foc <3 y	19	M/3	Mac/3 mo	Foc & SG	11 mo	SF	Autism	Dys	Thin CC; CD
22 M/7.2 DD/2 y NA NA NA NA PMG; hypoplastic CC 23 M/20 DD/3 mo — — — Mild MR Hyp Thin CC; CVD 24 F/7.6 DD/2 y NA NA NA NA N Thin CC; CVD 25 M/33.1 DD/3 y Foc <3 y	20	M/3.3	Mac/7mo	Foc	2 y	SF	Mild DD	Нур	No additional findings
23 M/20 DD/3 mo — — — Mild MR Hyp Thin CC; CVD 24 F/7.6 DD/2 y NA NA NA NA N Thin CC; CVD 25 M/33.1 DD/3 y Foc <3 y SF Mild MR Hemiplegia PMG; thin CC; CVD 26 F/30.7 E/30 y Foc & SG 30 y SF N N Thin CC; CVD 27 F/2.1 Hyp/2 y NA NA NA Mild DD A, Dys CD 28 F/11 Ob/2 y — — — Mild MR A, Dys ACF; CD 29 F/11 DD/6 y — — — Mild DD Hemiplegia CC and CVD 31 M/5.1 NA/NA NA NA NA DD A, Dys ACF; CD 32 F/2.5 A/1.6 y — — — Mild DD Dys, Dysm CD 33 M/22 M	21	F/50.3	DD/3 y	Foc	7 y	Monthly	Mild MR	Dysm	CD
24 F/7.6 DD/2 y NA Thin CC; CD 25 M/33.1 DD/3 y Foc & SG 30 y SF Mild MR Hemiplegia PMG; thin CC; CD 26 F/30.7 E/30 y Foc & SG 30 y SF N N Thin CC; CVD 27 F/2.1 Hyp/2 y NA NA NA Mild DD A, Dys ACF; CD 28 F/11 Ob/2 y — — — Mild MR A, Dys ACF; CD 29 F/11 DD/6 y — — — Mild DD Hemiplegia CC and CVD 31 M/5.1 DD/2 y — — Mild DD Hemiplegia CC and CVD 32 F/2.5 A/1.6 y — — Mild DD Dys, Dysm CD 33 M/22 Mic/1 mo Foc 2 y SF Autism Normal CC	22	M/7.2	DD/2 y	NA	NA	NA	NA	NA	PMG; hypoplastic CC
25 M/33.1 DD/3 y Foc <3 y	23	M/20	DD/3 mo	_	_	_	Mild MR	Нур	Thin CC; CVD
26 F/30.7 E/30 y Foc & SG 30 y SF N N Thin CC; CVD 27 F/2.1 Hyp/2 y NA NA NA NA Mild DD A, Dys CD 28 F/11 Ob/2 y — — — Mild MR A, Dys ACF; CD 29 F/11 DD/6 y — — — N A, Dys ACF; CD 30 F/2.1 DD/2 y — — — Mild DD Hemiplegia CC and CVD 31 M/5.1 NA/NA NA NA NA DD A, Dys ACF; CD 32 F/2.5 A/1.6 y — — — Mild DD Dys, Dysm CD 33 M/22 Mic/1 mo Foc 2 y SF Autism Normal CC hypoplasia 34 F/7.2 DD/2 y — — — Mild MR A Thin CC; CVD 35 F/8.5	24	F/7.6	DD/2 y	NA	NA	NA	NA	N	Thin CC; CD
27 F/2.1 Hyp/2 y NA NA NA Mild DD A, Dys CD 28 F/11 Ob/2 y — — — Mild MR A, Dys ACF; CD 29 F/11 DD/6 y — — — N A, Dys ACF; CD 30 F/2.1 DD/2 y — — — Mild DD Hemiplegia CC and CVD 31 M/5.1 NA/NA NA NA DD A, Dys ACF; CD 32 F/2.5 A/1.6 y — — — Mild DD Dys, Dysm CD 33 M/22 Mic/1 mo Foc 2 y SF Autism Normal CC hypoplasia 34 F/7.2 DD/2 y — — — Mild MR A Thin CC; CVD 35 F/8.5 Nys/3 mo — — — N A, apraxia Thin CC; CVD 36 M/4.8 Squint/1y Feb & SG </th <th>25</th> <th>M/33.1</th> <th>DD/3 y</th> <th>Foc</th> <th><3 y</th> <th>SF</th> <th>Mild MR</th> <th>Hemiplegia</th> <th>PMG; thin CC; CD</th>	25	M/33.1	DD/3 y	Foc	<3 y	SF	Mild MR	Hemiplegia	PMG; thin CC; CD
28 F/11 Ob/2 y — — — Mild MR A, Dys ACF; CD 29 F/11 DD/6 y — — — N A, Dys ACF; CD 30 F/2.1 DD/2 y — — — Mild DD Hemiplegia CC and CVD 31 M/5.1 NA/NA NA NA NA DD A, Dys ACF; CD 32 F/2.5 A/1.6 y — — — Mild DD Dys, Dysm CD 33 M/22 Mic/1 mo Foc 2 y SF Autism Normal CC hypoplasia 34 F/7.2 DD/2 y — — — Mild MR A Thin CC; CVD 35 F/8.5 Nys/3 mo — — — N A, apraxia Thin CC; CVD 36 M/4.8 Squint/1y Feb & SG 2 y SF N Esotropia Thin CC; CVD 37 F/4.1 E	26	F/30.7	E/30 y	Foc & SG	30 y	SF	N	N	Thin CC; CVD
29 F/11 DD/6 y — — — N A, Dys ACF; CD 30 F/2.1 DD/2 y — — — Mild DD Hemiplegia CC and CVD 31 M/5.1 NA/NA NA NA NA DD A, Dys ACF; CD 32 F/2.5 A/1.6 y — — — Mild DD Dys, Dysm CD 33 M/22 Mic/1 mo Foc 2 y SF Autism Normal CC hypoplasia 34 F/7.2 DD/2 y — — — Mild MR A Thin CC; CVD 35 F/8.5 Nys/3 mo — — — N A, apraxia Thin CC; CVD 36 M/4.8 Squint/1y Feb & SG 2 y SF N Esotropia Thin CC; CVD 37 F/4.1 E/1 y Foc 1 y Monthly Learn dis Ptosis, Hyp CD 38 F/4.1 E/1.6 y	27	F/2.1	Hyp/2 y	NA	NA	NA	Mild DD	A, Dys	CD
30 F/2.1 DD/2 y — — Mild DD Hemiplegia CC and CVD 31 M/5.1 NA/NA NA NA NA DD A, Dys ACF; CD 32 F/2.5 A/1.6 y — — — Mild DD Dys, Dysm CD 33 M/22 Mic/1 mo Foc 2 y SF Autism Normal CC hypoplasia 34 F/7.2 DD/2 y — — — Mild MR A Thin CC; CVD 35 F/8.5 Nys/3 mo — — — N A, apraxia Thin CC; CVD 36 M/4.8 Squint/1y Feb & SG 2 y SF N Esotropia Thin CC; CVD 37 F/4.1 E/1 y Foc 1 y Monthly N N CC agenesis 39 F/23.1 E/first day Foc & SG 2 d Monthly N N Thin CC	28	F/11	Ob/2 y	_	_	_	Mild MR	A, Dys	ACF; CD
31 M/5.1 NA/NA NA NA NA DD A, Dys ACF; CD 32 F/2.5 A/1.6 y — — — Mild DD Dys, Dysm CD 33 M/22 Mic/1 mo Foc 2 y SF Autism Normal CC hypoplasia 34 F/7.2 DD/2 y — — — Mild MR A Thin CC; CVD 35 F/8.5 Nys/3 mo — — N A, apraxia Thin CC; CVD 36 M/4.8 Squint/1y Feb & SG 2 y SF N Esotropia Thin CC; CVD 37 F/4.1 E/1 y Foc 1 y Monthly Learn dis Ptosis, Hyp CD 38 F/4.1 E/1.6 y Foc 1.6 mo Monthly N N N CC agenesis 39 F/23.1 E/first day Foc & SG 2 d Monthly N N Thin CC	29	F/11	DD/6 y	_	-	_	N	A, Dys	ACF; CD
32 F/2.5 A/1.6 y — — — Mild DD Dys, Dysm CD 33 M/22 Mic/1 mo Foc 2 y SF Autism Normal CC hypoplasia 34 F/7.2 DD/2 y — — — Mild MR A Thin CC; CVD 35 F/8.5 Nys/3 mo — — N A, apraxia Thin CC; CVD 36 M/4.8 Squint/1y Feb & SG 2 y SF N Esotropia Thin CC; CVD 37 F/4.1 E/1 y Foc 1 y Monthly Learn dis Ptosis, Hyp CD 38 F/4.1 E/1.6 y Foc 1.6 mo Monthly N N N Thin CC 39 F/23.1 E/first day Foc & SG 2 d Monthly N N Thin CC	30	F/2.1	DD/2 y	_	-	_	Mild DD	Hemiplegia	CC and CVD
33 M/22 Mic/1 mo Foc 2 y SF Autism Normal CC hypoplasia 34 F/7.2 DD/2 y — — — Mild MR A Thin CC; CVD 35 F/8.5 Nys/3 mo — — N A, apraxia Thin CC; CVD 36 M/4.8 Squint/1y Feb & SG 2 y SF N Esotropia Thin CC; CVD 37 F/4.1 E/1 y Foc 1 y Monthly Learn dis Ptosis, Hyp CD 38 F/4.1 E/1.6 y Foc 1.6 mo Monthly N N N CC agenesis 39 F/23.1 E/first day Foc & SG 2 d Monthly N N Thin CC	31	M/5.1	NA/NA	NA	NA	NA	DD	A, Dys	ACF; CD
34 F/7.2 DD/2 y — — — Mild MR A Thin CC; CVD 35 F/8.5 Nys/3 mo — — — N A, apraxia Thin CC; CVD 36 M/4.8 Squint/1y Feb & SG 2 y SF N Esotropia Thin CC; CVD 37 F/4.1 E/1 y Foc 1 y Monthly Learn dis Ptosis, Hyp CD 38 F/4.1 E/1.6 y Foc 1.6 mo Monthly N N CC agenesis 39 F/23.1 E/first day Foc & SG 2 d Monthly N N Thin CC	32		A/1.6 y	-	-	-	Mild DD	Dys, Dysm	CD
35 F/8.5 Nys/3 mo — — — — N A, apraxia Thin CC; CVD 36 M/4.8 Squint/1y Feb & SG 2 y SF N Esotropia Thin CC; CVD 37 F/4.1 E/1 y Foc 1 y Monthly Learn dis Ptosis, Hyp CD 38 F/4.1 E/1.6 y Foc 1.6 mo Monthly N N CC agenesis 39 F/23.1 E/first day Foc & SG 2 d Monthly N N Thin CC				Foc	2 у	SF	Autism	Normal	
36 M/4.8 Squint/1y Feb & SG 2 y SF N Esotropia Thin CC; CVD 37 F/4.1 E/1 y Foc 1 y Monthly Learn dis Ptosis, Hyp CD 38 F/4.1 E/1.6 y Foc 1.6 mo Monthly N N CC agenesis 39 F/23.1 E/first day Foc & SG 2 d Monthly N N Thin CC	34	F/7.2	DD/2 y	-	-	-	Mild MR	A	Thin CC; CVD
37 F/4.1 E/1 y Foc 1 y Monthly Learn dis Ptosis, Hyp CD 38 F/4.1 E/1.6 y Foc 1.6 mo Monthly N N CC agenesis 39 F/23.1 E/first day Foc & SG 2 d Monthly N N Thin CC	35		Nys/3 mo	-	-	-	N	A, apraxia	Thin CC; CVD
38 F/4.1 E/1.6 y Foc 1.6 mo Monthly N N CC agenesis 39 F/23.1 E/first day Foc & SG 2 d Monthly N N Thin CC	36			Feb & SG	2 у	SF			Thin CC; CVD
39 F/23.1 E/first day Foc & SG 2 d Monthly N N Thin CC	37		E/1 y	Foc	1 y	Monthly	Learn dis	Ptosis, Hyp	CD
	38		E/1.6 y		1.6 mo	,	N	N	-
40 F/5.1 DD/1.1 y Foc 5 y Monthly Mod MR A, Nys, Dys ACF; thin CC; CD	39		E/first day	Foc & SG	2 d	Monthly		N	Thin CC
	40	F/5.1	DD/1.1 y	Foc	5 y	Monthly	Mod MR	A, Nys, Dys	ACF; thin CC; CD
41 F/16.4 DD/prenatal — — Mod MR Ptosis, Hyp CD	41		DD/prenatal	-	-	-	Mod MR	Ptosis, Hyp	CD
42 M/6.4 E/10 mo Foc 10 mo DW Autism N Thin CC; CVD	42	M/6.4		Foc	10 mo	DW	Autism	N	Thin CC; CVD
43 M/7 DD/2 y Foc 2 y Monthly Mild MR Dys, Dysm CC agenesis; CD	43	M/7	DD/2 y	Foc	2 y	Monthly	Mild MR	Dys, Dysm	CC agenesis; CD
44 F/3.8 DD/2 y — — — Mod MR A, Hyp Thin CC; CD	44		DD/2 y	-	-	-	Mod MR	А, Нур	Thin CC; CD
45 M/4 DD/2 y — — — Mild MR Nys PMG; unilateral CD	45	M/4	DD/2 y	-	-	-	Mild MR	Nys	PMG; unilateral CD

—Continued

Table	Continued									
Patient	Sex/age, y	Reason for/age at referral	Seizure types	Age at seizure onset	Epilepsy outcome	Cognitive level and associated features	Neurologic examination	Brain MRI abnormalities associated with PNH and URH		
46	F/30	E/2 y	Foc & SG	2 y	SF	Autism	N	CD		
47	M/5.4	E/1.8 y	Foc & SG	1.8 y	Monthly	Mild MR	N	Thin CC; CD		
48	F/7	E/5.9 y	Foc	7 y	SF	Mild MR	N	CD		
49	M/10	Nys/2 y	_	_	_	Autism	Nys, A	Thin CC; CD		
50	M/19	E/15 y	Foc		SF	N	N	CD		

Abbreviations: A = ataxia; ACF = abnormal cortical folding; CC = corpus callosum; CD = cerebellar dysgenesis; CVD = cerebellar vermis dysgenesis; DD = developmental delay; DW = daily-weekly; Dys = dysarthria; Dysm = dysmetria; E = epilepsy; Feb = febrile; Foc = focal; Hyp = hypotonia; Learn dis = learning disabilities; LGS = Lennox Gastaut syndrome; Mac = macrocephaly; Mic = microcephaly; Mod = moderate; MR = mental retardation; N = normal; NA = not available; Nys = nystagmus; Ob = obesity; PMG = polymicrogyria; PNH = periventricular nodular heterotopia; SF = seizure-free; SG = secondarily generalized; URH = under-rotated hippocampi.

years). Duration of follow-up, known for 47 patients, ranged from 1 month to 47 years (mean 7.6 years; median 4.5 years).

Thirty-one patients (62%) had epilepsy. Age at seizure onset ranged from the first day of life to 30 years (mean 7.3 years; median 3 years). Of the 31 patients with epilepsy, 15 patients (33%) were seizure-free on antiepileptic drugs; 8 patients (16%) had monthly seizures; 7 patients (14%) had weeklydaily seizures; and 1 patient had isolated seizure (2%).

Twenty-eight patients (56%) had cerebellar signs including hypotonia, ataxia, dysmetria, tremor, and nystagmus. Twenty-eight patients (56%) exhibited mild to moderate cognitive impairment; 6 patients (12%) had autistic spectrum disorder. Fourteen patients (28%) had normal cognition, of whom 5 (35% of those with normal cognition) had cerebellar signs.

Thirty-five (70%) patients had been referred within the first 3 years of life: 20 (40%) for investigation of delayed milestones, hypotonia, and cerebellar signs; 8 (16%) for microcephaly, macrocephaly, or obesity; and 7 (14%) for epilepsy. For the remaining patients, referral was at a later age: in 2 patients (4%) for cerebellar signs and 11 patients (22%) for epilepsy alone. For 2 patients (4%), information about age at referral was unavailable.

MRI scan of the brain showed that in 28 patients (56%) the lateral ventricles were mildly enlarged posteriorly, with multiple bilateral nodules of heterotopic gray matter, predominantly adjacent to the trigones, the occipital, and the temporal horns (figure 1). The cortex was normal in 38 patients (76%), exhibited abnormal cortical folding consistent with parieto-occipital polymicrogyria in 4 patients (8%), with bilateral perisylvian polymicrogyria in 3 patients (6%), posterior and bilateral perisylvian polymicrogyria in 3 patients (6%), and frontal polymicrogyria in 2 patients (4%). In all patients the hippocampi were under-rotated and rounded; in 5 patients (10%) the hippocampal formation merged with the hetero-

topia, with loss of its typical shape, contour, and architecture (figure 1). The corpus callosum was diffusely thin in 24 patients (48%), with partial or complete agenesis in 6 patients (12%).


Forty-two patients (84%) had cerebellar abnormalities, including cerebellar dysgenesis in 27 patients (54%), unilateral hemispheric dysgenesis in 4 patients (88%), and isolated vermis dysgenesis in 11 patients (22%).

Mutation analysis of FLNA. No mutations of FLNA were found in the 33 individuals examined.

Gender bias. There was no evidence of gender bias or uneven gender distribution for age at referral (Fisher exact p = 0.17), clinical (Fisher exact p = 0.2), and anatomic severity (Fisher exact p = 0.12).

Neuropathologic study of the brain. We performed an anatomo-pathologic study of the brain in a female fetus after pregnancy termination at 20 weeks, after prenatal ultrasound revealed ventricular dilatation, enlargement of the cisterna magna, and absent corpus callosum. The brain surface was smooth with well-developed Sylvian fissures. The cerebellum was small and the posterior fourth ventricle visible (figure 2). Coronal slicing of the brain revealed ventriculomegaly and multiple subependymal nodules in the posterior halves of both ventricles. Some of the periventricular heterotopia were related to abnormal overlying white matter containing columns or clusters of immature neurons and patchy vascular proliferation. The overlying cortex showed a range of changes from normal or mild irregularity to focal pial disruption and florid overmigration of cells into the leptomeninges with proliferation of blood vessels and connective tissue (figure 3). Nowhere did the cortical malformation resemble polymicrogyria. The hippocampi were simple and poorly folded and the cerebellum was severely hypoplastic.

There was focal disruption of the cerebellar cortex and the dentate nucleus consisted of separate nodules




Patient 9: G, O; patient 15: A; patient 17: K; patient 18: P; patient 19: B; patient 21: C, M, S; patient 22: L, T; patient 25: E; patient 27: D, I, R; patient 31: F, H, J, N; patient 46: Q. Images A-E are sagittal cuts through the midline in 5 different patients; they show the morphology and shape of the corpus callosum, the vermis, and the posterior fossa. All patients exhibit cerebellar vermis dysgenesis, ranging from severe to mild, with mega cisterna magna (white and dark stars). Note the variable shape and size of the corpus callosum which is arcuate with loss of the distinction between genu and body in A, thinned in B, and dysmorphic in E. Images F to J include axial (F, G), coronal (H, I) cuts and a 3-dimensional reconstruction in 3 patients and show a range of cerebellar malformations, including pancerebellar dysgenesis in F, H, I, and J and unilateral dysgenesis in G (arrows and stars). Note the empty posterior fossa in H and I (stars) where bilateral periventricular heterotopia is also visible. Images K to O include sagittal (K, L, M) and axial (N, O) cuts in 5 patients. K to M show in detail the location of the heterotopic nodules (arrows) within the temporal horn. Note that in L and M heterotopia merges with the hippocampal formation. N and O show how the areas of heterotopia extend from the anteromesial aspect of the temporal horns back to their occipital aspect. Images P to T are coronal cuts in 5 different patients; they show the morphology of the hippocampi (arrows in P to T) and trigones (arrows in T) and the distribution of heterotopia in these regions (arrows). The hippocampal formation is either under-rotated or ill-defined and merges with the heterotopia, which reaches to the tip of the temporal horns.

rather than a continuous undulating band. The inferior olivary nucleus was simple with a thick dorsal limb.

DISCUSSION The 50 patients reported here shared similarities in brain abnormalities and clinical presentation. MRI scans of the brain showed nodular masses of gray matter restricted to the trigones and temporal and occipital horns. On both sides, heterotopic gray matter surrounded hippocampal formations that appeared under-rotated and rounded. The cortex was normal in 76%; in the remaining patients

we observed abnormal cortical folding consistent with posterior polymicrogyria, bilateral perisylvian polymicrogyria, and anterior polymicrogyria. An abnormally thin corpus callosum was observed in 48% of patients and callosal agenesis in 12%. Fifty-four percent of patients also had cerebellar hemispheric dysgenesis with moderate to severe dysgenesis of the vermis. In 40% of patients, delayed motor milestones were noticed before the third year of life, prompting neuroradiologic investigations and an early diagnosis of PNH. Cerebellar dysgenesis may

Figure 2 Macroscopic anatomo-pathologic images of the brain in a 20-week fetus



(A) Complete image of the brain shows a small cerebellum. (B) Coronal slice from occipital region shows multiple nodules in the walls of the lateral ventricles (arrows). (C) Coronal slice through the frontal region of fixed brain shows normal development and presence of corpus callosum.


explain the motor disability, muscular hypotonia, incoordination, and impaired development in these patients. Overall, cognitive abilities ranged from normal to moderately impaired, as reported in classic bilateral PNH. The finding that 12% of patients had an autistic spectrum disorder might be initially surprising, but not after considering the strong evidence linking autism with cerebellar dysgenesis. 13-15 Indeed, 5 out of the 6 children with autism had a cerebellar abnormality, including cerebellar dysgenesis in 4 and cerebellar vermis dysgenesis in 1. Although there was a continuum of severity of cerebellar malformation in the whole series, with no distinct degrees of severity, we appreciated that children with autism were among those with more severe cerebellar dysgenesis.

Autism has not been reported in association with *FLNA*-related PNH. In 38% of patients, the reason for referral was epilepsy. As with classic PNH linked to *FLNA* mutations, no distinctive epilepsy phenotype was observed.² Fourteen percent of patients had been referred for medical attention due to micro-

cephaly, macrocephaly, or obesity. There may be differences in the accuracy with which clinical information was collected in this series, due to the international collection of data. This limitation is unavoidable, however, when dealing with relatively rare disorders.

The pattern of brain malformation in these patients differs from that observed in association with FLNA mutations. The most obvious difference is in the location of the heterotopic nodules, which in classic bilateral PNH are usually diffuse but prominent in the suprasylvian ventricular system and do not extend into the temporal horns or surround the incompletely rotated hippocampal formation. The under-rotation of the hippocampi may result from parahippocampal heterotopic nodules containing neuronal contingents that normally reach the hippocampus during neuronal migration. Incomplete hippocampal rotation is often observed in patients with neuronal migration disorders16 but may also occur as an isolated abnormality.¹⁷ Patients in this study had more severe cerebellar dysgenesis than that

Figure 3 Microscopic anatomo-pathologic images of the brain in a 20-week fetus with peritrigonal heterotopia and cerebellar dysgenesis and of a 21-week normal fetus



(A) Two nodules of immature cells are seen beneath the ventricular lining (arrows). In the overlying white matter a stream of ectopic migrating cells and above these the cortex is irregular with neurons breaking through the pial barrier into the leptomeninges; (B) the hippocampus is simple and incompletely folded (arrows). For comparison see (C), normal hippocampus at 21 weeks.

observed in patients with classic bilateral PNH due to FLNA mutations.4 The reason why cerebellar dysgenesis, often severe, is associated with posteriorly predominant PNH and under-rotated hippocampi, sometimes merging with the heterotopia, remains cryptic. In both mouse models and humans, regionspecific transcription factor genes have been characterized that are primarily expressed in both the cerebellum and archicortex, such as Neurod218 and OTX2. OTX2 is expressed at an early stage in proliferative cell layers of the human fetal brain and plays an important role in neuronal cell development and differentiation in the archicortex, rostral brainstem, and cerebellum.19 Abnormal expression of a transcription factor with a similar expression pattern might explain a region-selective malformation, involving the hippocampi and cerebellum. Considering that heterotopia was close to, or merged with, the hippocampal formation, it is also possible that abnormally migrated neurons were destined to the archicortex.

Neuropathologic examination of the fetal brain revealed that, despite the topographic differences in the location of heterotopic nodules, their cytoarchitectonic characteristics were similar. However, there were abnormalities in the overlying white matter and focal overmigration of cortical cells and vascular proliferation. This abnormality indicates an association between the heterotopia and surface pial disruption and may be the precursor of the cortical dysplasia with abnormal vessels described in the mature brain with FLNA mutation.20 There was however no evidence of polymicrogyria which has been described in a neonate with FLNA mutation²¹ and in other forms of PNH5 indicating the heterogeneous nature of malformations labeled as polymicrogyria.^{22,23} The cerebellar involvement was more severe compared with FLNA-related heterotopia. The hippocampus appeared to be more simple and under-rotated than is usual in a 22-week-old fetal brain.

Mutation analysis of FLNA, performed in 33 patients, gave negative results. Our previous experience indicated that mutations of FLNA are found in up to 26% of sporadic patients with classic bilateral PNH³ and in only 4% of other phenotypic subclasses of PNH, including PNH with Ehlers-Danlos syndrome²⁴ and unilateral PNH. FLNA cannot be completely ruled out as the causative gene in all patients of this cohort, as mutation in noncoding regions, larger deletions/duplications involving 1 or more exons, and cryptic chromosomal abnormalities involving FLNA might still be present. We found no significant skewing of gender in our cohort, however, making an X-linked pattern of inheritance unlikely. The cohort included a mother and her son both affected; the remaining 48 patients were apparently sporadic.

Our observation suggests that an accurate clinical and neuroradiologic evaluation of patients with periventricular heterotopia can lead to the identification of specific subentities, each one possibly associated with a specific genetic defect.

AUTHOR CONTRIBUTIONS

Study concept and design: Drs. Guerrini, Pisano, Leventer, Blaser, Dobyns, and Barkovich. Acquisition of data: Drs. Pisano, Leventer, Barkovich, Squier, Scheffer, Marini, Robertson, Berkovic, Tortorella, Rosenow, Thomas, McGillivray, E. Andermann, F. Andermann, and Dobyns. Analysis and interpretation of data: Drs. Guerrini, Pisano, Squier, Dobyns, and Barkovich. Drafting of the manuscript: Drs. Pisano and Guerrini. Critical revision of the manuscript for important intellectual content: Drs. Barkovich, Berkovic, Scheffer, McGillivray, Rosenow, Tortorella, Blaser, E. Andermann, F. Andermann, Robertson, Squier, Marini, Leventer, Thomas, and Dobyns. Obtained funding: Dr. Guerrini. Administrative, technical, and material support: Drs. Guerrini, Barkovich, Scheffer, Parrini, Thomas, and Dobyns. Study supervision: Dr. Guerrini.

DISCLOSURE

T. Pisano reports no disclosures. A.J. Barkovich receives research support from NIH/NINDS and NIH/NIBIB. R. Leventer and W. Squier report no disclosures. I. Scheffer has received honoraria from GlaxoSmithKline, UCB, Biocodex, Athena Diagnostics, Janssen-Cilag, and Eli Lilly. She has pending patents entitled: Therapeutic compound: patent number: 61/ 010176; countries of patent: patent types: application year: 2008. She has received research support from the National Health and Medical Research Council of Australia: Health Research Council of New Zealand, NIH University of Melbourne, Austin Health Medical Research Foundation, Brockhoff Foundation, Perpetual Charitable Trustees, ANZ Trustees, Child Health Research Foundation, and Shepherd Foundation. E. Parrini and S. Blaser report no disclosures. C. Marini has received research support from Sixth Framework Thematic Priority Life sciences, Genomics and Biotechnology for Health, the Italian Ministry of Health and Education, and the Mariani Foundation. S. Robertson and G. Tortorella report no disclosures. F. Rosenow has received Scientific Advisory Boards from UCB, GSK, Pfizer, Eisai, and received honoraria from UCB. G. McGillivray has received honoraria from Roche and works as geneticist at Victorian Clinical Genetics Service. E. Andermann has received honoraria from UCB and has received research support from Sunovion Pharma, UCB, Santhera Pharma, and NINDS/NIH. F. Andermann reports no disclosures relevant to the manuscript. S. Berkovic was in the Scientific Advisory Boards: UCB SV2A. He has received honoraria from UCB. He is one of the inventors listed on a patent held by Bionomics Inc on diagnostic testing of using the SCN1A gene. He receives research support from UCB, Novartis, Sanofi Aventis, National Health, and Medical Research Council of Australia. W. Dobyns receives research support from NIH. R. Guerrini has received honoraria from Biocodex, UCB, Eisai Inc, ValueBox, and EMA (European Medicine Agency). He receives research support from the Italian Ministry of Health, the European Community Sixth Framework Thematic Priority Life Sciences, Genomics and Biotechnology for Health, the Italian Ministry of Education, University and Research, the Tuscany Region, the Telethon Foundation, and the Mariani Foundation. Go to Neurology.org for full disclosures.

Received November 11, 2011. Accepted in final form February 29, 2012.

REFERENCES

- Barkovich AJ, Kuzniecky RI, Jackson GD, Guerrini R, Dobyns WB. A developmental and genetic classification for malformations of cortical development. Neurology 2005;65:1873–1887.
- Parrini E, Ramazzotti A, Dobyns WB, et al. Periventricular heterotopia: phenotypic heterogeneity and correlation with Filamin A mutations. Brain 2006;129:1892–1906.
- Fox JW, Lamperti ED, Eksioglu YZ, et al. Mutations in filamin 1 prevent migration of cerebral cortical neurons in

- human periventricular heterotopia. Neuron 1998;21: 1315–1325.
- Wieck G, Leventer RJ, Squier WM, et al. Periventricular nodular heterotopia with overlying polymicrogyria. Brain 2005;28:2811–2821.
- Sheen VL, Dixon PH, Fox JW, et al. Mutations in the X-linked filamin 1 gene cause periventricular nodular heterotopia in males as well as in females. Hum Mol Genet 2001;10:1775–1783.
- Guerrini R, Dobyns WB, Barkovich AJ. Abnormal development of the human cerebral cortex: genetics, functional consequences and treatment options. Trends Neurosci 2008;31:154–162.
- Online Mendelian inheritance in man. Available at: http:// www.ncbi.nlm.nih.gov. Accessed November 8, 2011.
- Eksioglu YZ, Scheffer IE, Cardenas P, et al. Periventricular heterotopia: an X-linked dominant epilepsy locus causing aberrant cerebral cortical development. Neuron 1996;16:77–87.
- Dobyns WB, Andermann E, Andermann F, et al. X-linked malformations of neuronal migration. Neurology 1996; 47:331–339.
- Sloan W, Birch JW. A rationale for degrees of retardation. Am J Ment Defic 1955;60:258–264.
- Poretti A, Prayer D, Boltshauer E. Morphological spectrum of prenatal cerebellar disruptions. Eur J Paediatr Neurol 2009;13:397–407.
- 12. Guerrini R, Dobyns WB, Barkovich AJ. Abnormal development of the human cerebral cortex: genetics, functional consequences and treatment options. Trends Neurosci 2008;31:154–162.
- Elsen GE, Choi LY, Prince VE, Ho RK. The autism susceptibility gene met regulates zebrafish cerebellar development and facial motor neuron migration. Dev Biol 2009; 335:78–92.
- Gillig PM, Sanders RD. Psychiatry, neurology, and the role of the cerebellum. Psychiatry 2010;7:38–43.

- Sparks BF, Friedman SD, Swa DW, et al. Brain structural abnormalities in young children with autism spectrum disorder. Neurology 2002;59:184–192.
- Baulac M, De Grissac N, Hasboun D, et al. Hippocampal developmental changes in patients with partial epilepsy: magnetic resonance imaging and clinical aspects. Ann Neurol 1998;44:223–233.
- Fernandez G, Effenberger O, Vinz B, et al. Hippocampal malformation as a cause of familial febrile convulsions and subsequent hippocampal sclerosis. Neurology 1998;50: 909–917.
- Suzuki H, Okunishi R, Hashizume W, et al. Identification of region-specific transcription factor genes in the adult mouse brain by medium-scale real-time RT-PCR. FEBS Lett 2004;573:214–218.
- Larsen KB, Lutterodt MC, Møllgård K, Møller MJ. Expression of the homeobox genes OTX2 and OTX1 in the early developing human brain. Histochem Cytochem 2010;58:669–678.
- Kakita A, Hayashi S, Moro F, et al. Bilateral periventricular nodular heterotopia due to filamin 1 gene mutation: widespread glomeruloid microvascular anomaly and dysplastic cytoarchitecture in the cerebral cortex. Acta Neuropathol 2002;104:649–657.
- Guerrini R, Mei D, Sisodiya S, et al. Germline and mosaic mutations of FLN1 in men with periventricular heterotopia. Neurology 2004;63:51–56.
- 22. Barkovich AJ. MRI analysis of sulcation morphology in polymicrogyria. Epilepsia 2010;51:17–22.
- Li S, Jin Z, Koirala S, et al. GPR56 regulates pial basement membrane integrity and cortical lamination. J Neurosci 2008;28:5817–5826.
- Sheen VL, Walsh CA. Periventricular heterotopia: new insights into Ehlers-Danlos syndrome. Clin Med Res 2005; 3:229–233.

Thank you, Dr. John F. Kurtzke!

The Neurology online archive has recently been updated to include the following seminal articles related to early research in MS:

Rose AS, Kuzma JW, Kurtzke, JF, et al. Cooperative study in the evaluation of therapy in multiple sclerosis; ACTH vs placebo in acute exacerbations. Neurology 1968 (June); 18 (6 Part 2): 1–10.

Rose AS, Kuzma JW. A protocol for a cooperative study to evaluate the therapeutic effectiveness of ACTH on multiple sclerosis in acute exacerbations. Neurology 1968 (June); 18 (6 Part 2): 1–20 + study forms.

Rose AS, Kuzma JW, Kurtzke, JF, et al. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs. placebo – final report. Neurology 1970 (May); 20 (5 Part 2) 1–59.

Kurtzke, JF. Multiple Sclerosis: What's in a name? Neurology 1988;38:309-316.

The Editorial office acknowledges Dr. John F. Kurtzke for his assistance in filling these gaps.